These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20175693)

  • 41. The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316.
    Cunningham CK; Balasubramanian R; Delke I; Maupin R; Mofenson L; Dorenbaum A; Sullivan JL; Gonzalez-Garcia A; Thorpe E; Rathore M; Gelber RD
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):800-7. PubMed ID: 15213563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.
    Kallianpur AR; Wang Q; Jia P; Hulgan T; Zhao Z; Letendre SL; Ellis RJ; Heaton RK; Franklin DR; Barnholtz-Sloan J; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Grant I;
    J Infect Dis; 2016 Apr; 213(7):1065-73. PubMed ID: 26690344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients.
    Bai F; Iannuzzi F; Merlini E; Borghi L; Tincati C; Trunfio M; Bini T; Monforte AD; Marchetti G
    AIDS; 2017 Jan; 31(2):311-314. PubMed ID: 28005574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
    Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Barriers to Antiretroviral Therapy Adherence Among HIV-Positive Hispanic and Latino Men Who Have Sex with Men -United States, 2015-2019.
    Crim SM; Tie Y; Beer L; Weiser J; Dasgupta S
    MMWR Morb Mortal Wkly Rep; 2020 Oct; 69(40):1437-1442. PubMed ID: 33031362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders.
    Morgan EE; Woods SP; Letendre SL; Franklin DR; Bloss C; Goate A; Heaton RK; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Ellis RJ; Abramson I; Gamst A; Fennema-Notestine C; Smith DM; Grant I; Vaida F; Clifford DB;
    J Neurovirol; 2013 Apr; 19(2):150-6. PubMed ID: 23408335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
    Bhaskaran K; Mussini C; Antinori A; Walker AS; Dorrucci M; Sabin C; Phillips A; Porter K;
    Ann Neurol; 2008 Feb; 63(2):213-21. PubMed ID: 17894380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AIDS cases among women who reported sex with a bisexual man, 2000-2004--United States.
    Satcher AJ; Durant T; Hu X; Dean HD
    Women Health; 2007; 46(2-3):23-40. PubMed ID: 18160368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.
    Phillips A; Pezzotti P;
    AIDS; 2004 Jan; 18(1):51-8. PubMed ID: 15090829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline clinical characteristics, antiretroviral therapy use, and viral load suppression among HIV-positive young men of color who have sex with men.
    Hightow-Weidman LB; Jones K; Phillips G; Wohl A; Giordano TP;
    AIDS Patient Care STDS; 2011 Aug; 25 Suppl 1(Suppl 1):S9-14. PubMed ID: 21711145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy.
    Vera JH; Ridha B; Gilleece Y; Amlani A; Thorburn P; Dizdarevic S
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):895-902. PubMed ID: 28058461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Towards achieving the 90-90-90 HIV targets: results from the south African 2017 national HIV survey.
    Marinda E; Simbayi L; Zuma K; Zungu N; Moyo S; Kondlo L; Jooste S; Nadol P; Igumbor E; Dietrich C; Briggs-Hagen M
    BMC Public Health; 2020 Sep; 20(1):1375. PubMed ID: 32907565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychological and social determinants of health, antiretroviral therapy (ART) adherence, and viral suppression among HIV-positive black women in care.
    Bradley ELP; Frazier EL; Carree T; Hubbard McCree D; Sutton MY
    AIDS Care; 2019 Aug; 31(8):932-941. PubMed ID: 31056924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals.
    Smith PR; Sarner L; Murphy M; James B; Thomas JM; Skinner CJ; Aitken C
    J Clin Virol; 2003 Jan; 26(1):101-7. PubMed ID: 12589840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment.
    Ironson G; O'Cleirigh C; Fletcher MA; Laurenceau JP; Balbin E; Klimas N; Schneiderman N; Solomon G
    Psychosom Med; 2005; 67(6):1013-21. PubMed ID: 16314608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
    Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
    AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rates of prevalent and new HIV diagnoses by race and ethnicity among men who have sex with men, U.S. states, 2013-2014.
    Rosenberg ES; Purcell DW; Grey JA; Hankin-Wei A; Hall E; Sullivan PS
    Ann Epidemiol; 2018 Dec; 28(12):865-873. PubMed ID: 29753640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.